Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our Best Content in Your Email

You are already a member! Please enter your password to sign in.

Arrowhead to Present at Upcoming Conferences


Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present data on the Dynamic Polyconjugate (DPC) siRNA delivery technology at two upcoming scientific conferences.

Scheduled conference presentations include the following:

EuroTIDES 2013 – Prague, Czech Republic, November 13-14

November 14, 2013 – An oral presentation titled, “DPC technology for delivery of therapeutic siRNAs,” will be presented by David Lewis, Ph.D., Chief Scientific Officer;

Oligonucleotide & Peptide Based Therapeutics Congress – San Diego, CA, USA, November 18-19

November 19, 2013 – An oral presentation titled, “Targeted delivery of therapeutic siRNAs using DPC technology,” will be presented by David Lewis, Ph.D., Chief Scientific Officer.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary drug delivery technologies to develop targeted drugs based on the RNA interference mechanism that efficiently silence disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus and obesity and partner-based programs in oncology.

For more information please visit, or follow us on Twitter @ArrowRes. To be added to the Company’s email list to receive news directly, please send an email to

Rate this press release
3 stars


Add to favourites icon Add to favourites